Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POVAN vs BILTRICIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pyrvinium pamoate inhibits oxidative metabolism and glucose uptake in susceptible helminths, leading to energy depletion and paralysis of the worm. It also binds to DNA and inhibits RNA synthesis in the parasite.
Praziquantel increases the permeability of cell membranes to calcium ions in susceptible schistosomes and other trematodes, causing sustained contraction and paralysis of the worm musculature, leading to detachment from blood vessel walls and eventual death.
Treatment of enterobiasis (pinworm infection) caused by Enterobius vermicularis
Treatment of schistosomiasis (all species),Treatment of clonorchiasis sinensis (liver fluke),Treatment of opisthorchiasis (liver fluke),Off-label: Treatment of neurocysticercosis (in combination with corticosteroids),Off-label: Treatment of other trematode infections (e.g., fasciolopsiasis, intestinal flukes),Off-label: Treatment of cestode infections (e.g., diphyllobothriasis, taeniasis)
Pyrantel pamoate: 11 mg/kg (maximum 1 g) orally once; repeat in 2 weeks for pinworm. For ascariasis, hookworm, trichostrongyliasis: 11 mg/kg (max 1 g) once daily for 3 days.
60 mg/kg/day orally in 3 divided doses (20 mg/kg/dose) for 1 day.
Terminal elimination half-life is approximately 16 hours; clinically, this supports single-dose administration with slow elimination
Terminal elimination half-life is approximately 0.8-1.5 hours for praziquantel; clinical significance: short half-life necessitates multiple dosing for sustained antiparasitic effect.
Pyrvinium pamoate is minimally absorbed from the gastrointestinal tract; systemic metabolism is negligible. The small absorbed fraction is metabolized in the liver, but specific enzymes are not well defined.
Extensively metabolized by the liver, primarily by cytochrome P450 enzymes (CYP3A4), to inactive hydroxylated metabolites.
Primarily fecal (90%) as unchanged drug via bile; renal excretion is minimal (<1%)
Renal excretion accounts for approximately 80-90% of elimination, primarily as metabolites; biliary/fecal excretion is minor (<10%).
Bound to plasma proteins (especially albumin) approximately 75–80%
Approximately 80-85% bound to serum albumin.
Apparent volume of distribution is 0.5–0.7 L/kg, consistent with moderate tissue distribution
Volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution.
Oral bioavailability is low (<10%) due to poor absorption; acts topically in the GI tract
Oral bioavailability is approximately 80% due to extensive first-pass metabolism; higher with food.
No specific guidelines; caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No dosage adjustment required for any degree of renal impairment.
Contraindicated in acute hepatic disease or significant liver impairment (Child-Pugh class B or C); use not recommended.
No specific Child-Pugh based adjustments; contraindicated in hepatocellular carcinoma or history of hepatic encephalopathy; use caution in severe liver disease.
Weight-based: 11 mg/kg (maximum 1 g) orally once for pinworm; repeat in 2 weeks. For other infections: 11 mg/kg once daily for 3 days.
4 years and older: 60 mg/kg/day in 3 divided doses for 1 day; maximum single dose 2 g.
No specific adjustments; use standard dosing with caution due to potential comorbidities and reduced hepatic function.
No specific adjustments; use standard adult dosing with monitoring for adverse effects.
None
None.
Gastrointestinal disturbances may occur; caution in patients with inflammatory bowel disease or severe hepatic impairment. May cause staining of stools and emesis. Avoid in pregnancy unless clearly needed.
Avoid grapefruit juice during treatment due to increased praziquantel exposure.,May cause transient neurologic symptoms in patients with cerebral schistosomiasis or neurocysticercosis due to inflammatory reaction around dying parasites.,Use with caution in patients with hepatic impairment (Child-Pugh class B or C) as metabolism may be reduced.,May exacerbate cysticercosis if used without corticosteroids in neurocysticercosis.,Potential for cardiac arrhythmias in patients with ventricular arrhythmias or electrolyte disturbances (rare).
Hypersensitivity to pyrvinium or any component of the formulation,Intestinal obstruction or acute abdominal conditions
Hypersensitivity to praziquantel or any component of the formulation,Ocular cysticercosis (due to risk of irreversible ocular damage from inflammatory response),Concurrent use with rifampin (significantly reduces praziquantel plasma concentrations),Children under 1 year of age (safety not established)
No specific food interactions. The drug should be taken with food to reduce gastrointestinal upset.
Take with food to enhance bioavailability. Avoid grapefruit juice as it may increase drug levels. Alcohol may worsen CNS side effects and is not recommended.
Pyrvinium pamoate (Povan) is not recommended during pregnancy due to insufficient human data. Animal studies have not shown teratogenicity, but risk cannot be excluded. In first trimester, avoid use unless clearly needed. Second and third trimester: consider risk-benefit; no known fetal harm from limited reports.
Praziquantel (Biltricide) is FDA Pregnancy Category B. Animal studies show no teratogenic effects but embryotoxicity at high doses. Human data limited; no increased risk of major malformations reported. Avoid in first trimester unless essential; use in second/third trimester if benefit outweighs risk.
Unknown if pyrvinium pamoate is excreted in human milk. M/P ratio not available. Caution advised, consider alternative treatment during breastfeeding.
Praziquantel is excreted into breast milk in small amounts; M/P ratio not established. After a single dose, milk levels low; consider pumping and discarding milk for 24-48 hours post-dose. Use with caution in nursing mothers.
No dose adjustment studied in pregnancy. Standard adult dose: 5 mg/kg base (max 350 mg) single dose. Use only if potential benefit justifies risk.
No dose adjustment required for pregnancy; standard dosing (20 mg/kg three times daily for 1 day) unless hepatic impairment present. Pharmacokinetics in pregnancy not significantly altered; unchanged recommendations.
POVAN (pyrvinium pamoate) is primarily used for enterobiasis (pinworm infection). Administer as a single oral dose; repeat after 2 weeks to prevent reinfection. Tablets should be swallowed whole to avoid staining teeth. Drug may turn stools red. Avoid in patients with gastrointestinal disorders or inflammatory bowel disease. Monitor for nausea, vomiting, and cramping.
Administer with food to increase absorption and reduce GI side effects. Use with caution in hepatic impairment; dose adjustment may be necessary. Monitor for neuropsychiatric effects (e.g., dizziness, headache) especially in patients with CNS involvement of schistosomiasis. Avoid in patients with ocular cysticercosis due to risk of intraocular inflammation; treat ocular lesions first with corticosteroids.
Take the medication exactly as a single dose, and repeat after 2 weeks.,Swallow tablets whole; do not crush or chew to prevent mouth staining.,Stools may appear bright red; this is harmless.,Wash hands thoroughly after using the toilet and before eating to prevent reinfection.,Wash bedding and underwear in hot water; vacuum floors to remove eggs.,Treat all household members simultaneously to avoid spread.,Report persistent abdominal pain or diarrhea to your doctor.
Take this medication with a meal to improve absorption and reduce stomach upset.,Do not chew or crush the tablets; swallow them whole.,Complete the full course of treatment even if you feel better.,You may experience dizziness, drowsiness, or headache; avoid driving or operating heavy machinery until you know how the drug affects you.,Inform your doctor if you have liver disease or are taking other medications.,Contact your doctor if you experience severe headache, seizures, or vision changes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POVAN vs BILTRICIDE, answered by our medical review team.
POVAN is a Anthelmintic that works by Pyrvinium pamoate inhibits oxidative metabolism and glucose uptake in susceptible helminths, leading to energy depletion and paralysis of the worm. It also binds to DNA and inhibits RNA synthesis in the parasite.. BILTRICIDE is a Anthelmintic that works by Praziquantel increases the permeability of cell membranes to calcium ions in susceptible schistosomes and other trematodes, causing sustained contraction and paralysis of the worm musculature, leading to detachment from blood vessel walls and eventual death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POVAN and BILTRICIDE depend on the specific clinical indication. These are both Anthelmintic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POVAN is: Pyrantel pamoate: 11 mg/kg (maximum 1 g) orally once; repeat in 2 weeks for pinworm. For ascariasis, hookworm, trichostrongyliasis: 11 mg/kg (max 1 g) once daily for 3 days.. The standard adult dose of BILTRICIDE is: 60 mg/kg/day orally in 3 divided doses (20 mg/kg/dose) for 1 day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POVAN and BILTRICIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POVAN is classified as Category C. Pyrvinium pamoate (Povan) is not recommended during pregnancy due to insufficient human data. Animal studies have not shown teratogenicity, but risk cannot be excluded. In first tr. BILTRICIDE is classified as Category C. Praziquantel (Biltricide) is FDA Pregnancy Category B. Animal studies show no teratogenic effects but embryotoxicity at high doses. Human data limited; no increased risk of major m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.